Breathe Well Live Well
|
Monoclonal Antibody Dupilumab Safe And Effective In Asthma Phase IIa Trial
Science 2.0 A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to researchers. The randomized, double-blind, placebo-controlled trial tested the efficacy … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified March 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Dupilumab Could End of Being 'Blockbuster' Asthma Drug – Analyst (SNY) (REGN)
StreetInsider.com (subscription) Dupilumab may debut in 2018 as a treatment for skin and/or asthma conditions, Fernandez said. He observes the large market for asthma, with competition expected from the likes of AstraZenece (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), and others. |
View full post on asthma – Google News